Puerto Rican chemical industry news

30 October 2025
Lilly Q3 2025 Financials: Revenue Up 54%, R&D Progress, Guidance Raised
Revenue growth driven by incretin demand. Advanced orforglipron trials, FDA approval for Inluriyo. Expanded manufacturing in Virginia, Texas, Puerto Rico.
29 October 2025
Lilly Invests $1.2 Billion in Puerto Rico for U.S. Oral Medicine Manufacturing Expansion
The investment will create 100 manufacturing and 1,000 construction jobs, enhancing production of oral solid medicines with advanced technologies. Construction starts in 2026, production by 2028.

How does the Puerto Rican chemical industry perform?

Find out with chemXplore Analytics